Checkpoint inhibitors are monoclonal antibodies that block inhibitory “checkpoint” proteins such as PD‑1, PD‑L1, and CTLA‑4 on T cells or tumor cells, thereby releasing the brakes on the immune system and enhancing anti‑tumor activity. They are now a major class of cancer immunotherapy used across multiple solid tumors and lymphomas, often with durable responses in a subset of patients. The following is a list of APIs used as Checkpoint inhibitors.
Filters
Modal title
Thank you
Thank you for sending us request for the quotation. We will get back to you asap. Thank you
Thank you
Thank you for contacting us. We will get back to you asap. Thank you
Thank you
Thank you for request submission to join as consultant. We will get back to you asap. Thank you
Thank you
Thank you for request submission to become a supplier. We will get back to you asap. Thank you
Thank you
Thank you for enquiry. We will get back to you asap. Thank you
